



Financial Tear Sheet

Corporate Profile

C. R. Bard, Inc. is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of Vascular, Urology, Oncology and Surgical Specialty products.

Bard markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities.

Bard pioneered the development of single-patient-use medical products for hospital procedures; today Bard is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs.

Stock Information

BCR (Common Stock)

Exchange NYSE (US Dollar)

Price **\$331.24**

Change (%) 0.00 (0.00%)

Volume 0

52 Week High \$337.73


52 Week Low \$222.42

Data as of 12/28/17 4:02 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Primary IR Contact

Todd Garner
VP Investor Relations
Phone: 908-277-8065



Recent Press Releases & Upcoming Events

10/25/17

Bard Announces Third Quarter Results

10/11/17

Bard Declares Quarterly Dividend

08/28/17

C. R. Bard Receives FDA Premarket Approval of the LUTONIX® 035 Drug Coated Balloon as the First and Only DCB for the Treatment of Patients with Dysfunctional AV Fistulae

There are currently no events scheduled.

SEC Filings

Filing Date	Form
02/13/18	SC 13G/A
01/08/18	15-12B
01/03/18	4
01/03/18	4